{"id":"calcineurin-inhibitor-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Neurotoxicity (tremor, headache)"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Gingival hyperplasia"},{"rate":null,"effect":"Infections"}]},"_chembl":{"chemblId":"CHEMBL5715921","moleculeType":null,"molecularWeight":"652.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These agents inhibit calcineurin, a serine/threonine phosphatase essential for T-cell receptor signaling. By blocking calcineurin, they prevent the activation and proliferation of T lymphocytes, thereby reducing immune-mediated inflammation and rejection responses. This mechanism makes them effective immunosuppressants in transplantation and autoimmune conditions.","oneSentence":"Calcineurin inhibitors suppress T-cell activation by blocking the phosphatase calcineurin, preventing the dephosphorylation and nuclear translocation of NFAT transcription factors required for cytokine production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:38.907Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prophylaxis"},{"name":"Autoimmune and inflammatory disorders"}]},"trialDetails":[{"nctId":"NCT05917522","phase":"PHASE2","title":"Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Kidney Transplant","enrollment":800},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT07234838","phase":"","title":"Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)","status":"RECRUITING","sponsor":"Jonathan Krygier","startDate":"2026-02-01","conditions":"Psoriasis, Condyloma Acuminata, Biotherapies","enrollment":600},{"nctId":"NCT07224529","phase":"PHASE4","title":"Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Meibomian Gland Dysfunction (MGD)","enrollment":48},{"nctId":"NCT07204275","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-09-30","conditions":"Primary Membranous Nephropathy","enrollment":176},{"nctId":"NCT06305286","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-03-04","conditions":"Type 1 Diabetes Mellitus","enrollment":70},{"nctId":"NCT05894512","phase":"","title":"Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2023-06-01","conditions":"Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced, Membranous Nephropathy - THSD7A Induced","enrollment":44},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT07406932","phase":"NA","title":"A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome","status":"NOT_YET_RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2026-02-01","conditions":"Antisynthetase Syndrome, Interstitial Lung Disease (ILD)","enrollment":80},{"nctId":"NCT05288855","phase":"PHASE3","title":"Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis","status":"TERMINATED","sponsor":"Aurinia Pharmaceuticals Inc.","startDate":"2023-10-10","conditions":"Adolescent Lupus Nephritis, Pediatric Lupus Nephritis","enrollment":9},{"nctId":"NCT05962788","phase":"PHASE3","title":"Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis","status":"TERMINATED","sponsor":"Aurinia Pharmaceuticals Inc.","startDate":"2024-03-28","conditions":"Adolescent Lupus Nephritis, Pediatric Lupus Nephritis","enrollment":4},{"nctId":"NCT05621759","phase":"PHASE2","title":"Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-09-07","conditions":"Graft Vs Host Disease","enrollment":27},{"nctId":"NCT05704205","phase":"NA","title":"The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-02-22","conditions":"Atopic Dermatitis Eczema, Atopic Dermatitis","enrollment":316},{"nctId":"NCT05704738","phase":"PHASE3","title":"A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-04-20","conditions":"Atopic Dermatitis","enrollment":532},{"nctId":"NCT00133887","phase":"PHASE3","title":"TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2004-04","conditions":"Skin Cancer, Kidney Transplantation","enrollment":77},{"nctId":"NCT04745728","phase":"PHASE3","title":"Different Immunosuppressive Treatment in iMN","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-04-14","conditions":"Idiopathic Membranous Nephropathy","enrollment":200},{"nctId":"NCT07091175","phase":"PHASE2","title":"Dupilumab Therapy in Nephrotic Syndrome in Children","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-11-27","conditions":"Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-Dependent","enrollment":66},{"nctId":"NCT07240389","phase":"NA","title":"Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy.","status":"NOT_YET_RECRUITING","sponsor":"Milosz Pietrus","startDate":"2025-12-01","conditions":"Vulvar Lichen Sclerosus","enrollment":45},{"nctId":"NCT06881927","phase":"PHASE4","title":"Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-02-01","conditions":"Sepsis and Septic Shock, Acute Respiratory Failure, Kidney Transplant Recipients","enrollment":212},{"nctId":"NCT03320642","phase":"PHASE1","title":"GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2018-02-27","conditions":"Hematologic Malignancies","enrollment":84},{"nctId":"NCT03680092","phase":"PHASE2","title":"Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation","status":"COMPLETED","sponsor":"Dimitrios Tzachanis, MD PhD","startDate":"2019-11-26","conditions":"GVHD, Hematologic Neoplasms","enrollment":43},{"nctId":"NCT05579769","phase":"PHASE2","title":"Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-03-14","conditions":"Hematologic Malignancy, Myeloid Malignancy","enrollment":3},{"nctId":"NCT04202679","phase":"PHASE3","title":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-01-16","conditions":"Neurodermatitis","enrollment":160},{"nctId":"NCT04183335","phase":"PHASE3","title":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-12-12","conditions":"Neurodermatitis","enrollment":151},{"nctId":"NCT05646992","phase":"PHASE2, PHASE3","title":"Uterus Transplantation to Treat Infertility","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-03-01","conditions":"Uterine Factor Infertility","enrollment":40},{"nctId":"NCT06607991","phase":"PHASE1","title":"Blinatumomab for CNI-Resistant/Intolerant SRNS in Children","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2024-09-19","conditions":"CNI-resistant Steriod Resistant Nephrotic Syndrome, CNI-intolerent, Steriod Resistant Nephrotic Syndrome","enrollment":6},{"nctId":"NCT05660785","phase":"PHASE2","title":"Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-12-01","conditions":"Non Severe Aplastic Anemia, Untreated","enrollment":54},{"nctId":"NCT06880042","phase":"EARLY_PHASE1","title":"COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO","status":"ENROLLING_BY_INVITATION","sponsor":"Dr ayesha wahid","startDate":"2025-05-01","conditions":"Vitiligo - Macular Depigmentation, Tacrolimus","enrollment":60},{"nctId":"NCT02711202","phase":"NA","title":"Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2007-01","conditions":"Kidney Transplantation","enrollment":20},{"nctId":"NCT07003438","phase":"EARLY_PHASE1","title":"Study on the Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Steroid - Dependent /Steroid-resistant Nephrotic Syndrome in Children","status":"NOT_YET_RECRUITING","sponsor":"Zhang Ting","startDate":"2025-06-01","conditions":"Steroid-Resistant Nephrotic Syndrome, Steroid-Dependent Nephrotic Syndrome","enrollment":120},{"nctId":"NCT03828019","phase":"PHASE3","title":"Adalimumab vs. Conventional Immunosuppression for Uveitis Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2019-09-16","conditions":"Uveitis","enrollment":227},{"nctId":"NCT05706636","phase":"NA","title":"T Central Memory Cells in Early Localized Non-Segmental Vitiligo","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-02-01","conditions":"Vitiligo","enrollment":22},{"nctId":"NCT06942156","phase":"PHASE4","title":"Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2025-08-14","conditions":"Heart Transplant","enrollment":140},{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT05975450","phase":"PHASE1","title":"Subcutaneous Abatacept in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Idelberto Badell","startDate":"2023-08-02","conditions":"Kidney Transplant Recipient","enrollment":14},{"nctId":"NCT06493526","phase":"PHASE4","title":"Mycophenolate-Based Therapy for Kidney Transplant Recipients Without HLA-DQ Mismatch","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2024-08-20","conditions":"Kidney Transplantation","enrollment":20},{"nctId":"NCT04989491","phase":"PHASE4","title":"Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-12-01","conditions":"Epstein-Barr Virus Infections","enrollment":120},{"nctId":"NCT06400771","phase":"PHASE1","title":"Safety of DNP007 in Healthy Subjects","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2024-06-10","conditions":"Liver Transplant Rejection, Liver Transplant; Complications, Steatohepatitis, Nonalcoholic","enrollment":12},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT06203470","phase":"PHASE4","title":"Botox Versus Tacrolimus in Psoriasis Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-06","conditions":"Psoriasis Vulgaris","enrollment":60},{"nctId":"NCT03955172","phase":"NA","title":"Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2020-12-03","conditions":"Kidney Transplant Failure and Rejection","enrollment":20},{"nctId":"NCT06406205","phase":"PHASE3","title":"A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-12-25","conditions":"Lupus Nephritis","enrollment":270},{"nctId":"NCT04559048","phase":"","title":"Investigation of Pain Incidence After FK506 Immunosuppressive Therapy in Liver Transplantation Patients","status":"UNKNOWN","sponsor":"The Second Hospital of Tangshan","startDate":"2019-09-15","conditions":"Chronic Pain, Liver Transplantation","enrollment":300},{"nctId":"NCT05208788","phase":"","title":"Urinary Biomarkers in Paediatric Kidney Transplantation (pKTx)","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2021-06-01","conditions":"Renal Transplantation, Chronic Kidney Insufficiency, Healthy Controls","enrollment":186},{"nctId":"NCT06124885","phase":"NA","title":"Real-time Early Detection of Nephrotoxicity by Urinary Biomarker Analysis With SeroFlow Technology","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2023-11","conditions":"Acute Kidney Injury","enrollment":150},{"nctId":"NCT00685061","phase":"PHASE4","title":"Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation","status":"COMPLETED","sponsor":"University of Miami","startDate":"2002-11","conditions":"Renal Transplantation","enrollment":90},{"nctId":"NCT04888741","phase":"PHASE2","title":"Methods of T Cell Depletion Trial (MoTD)","status":"UNKNOWN","sponsor":"University of Birmingham","startDate":"2021-02-22","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia","enrollment":400},{"nctId":"NCT02533180","phase":"PHASE2","title":"Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-15","conditions":"Liver Transplant, Liver Transplantation","enrollment":100},{"nctId":"NCT00681343","phase":"PHASE4","title":"Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation","status":"COMPLETED","sponsor":"University of Miami","startDate":"2002-09","conditions":"Living-Donor Kidney Transplant","enrollment":38},{"nctId":"NCT00896012","phase":"PHASE4","title":"Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2008-01","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT02345850","phase":"PHASE3","title":"Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-08","conditions":"Acute Leukemia, Myelodysplasia","enrollment":346},{"nctId":"NCT05375435","phase":"PHASE4","title":"Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-01-01","conditions":"Dermatomyositis, Adult Type, Interstitial Lung Disease","enrollment":120},{"nctId":"NCT01935128","phase":"PHASE4","title":"Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction","status":"COMPLETED","sponsor":"University of Toledo Health Science Campus","startDate":"2013-07-03","conditions":"Renal Transplant","enrollment":55},{"nctId":"NCT05030974","phase":"PHASE4","title":"RECOVAC Repeated Vaccination Study","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2021-10-21","conditions":"Covid19, Kidney Diseases, Vaccine Response Impaired","enrollment":336},{"nctId":"NCT01560572","phase":"PHASE4","title":"Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2011-04","conditions":"Renal Insufficiency, Kidney Transplantation","enrollment":305},{"nctId":"NCT03539601","phase":"PHASE4","title":"A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-04-27","conditions":"Atopic Dermatitis","enrollment":237},{"nctId":"NCT04706559","phase":"NA","title":"Efficacy of Oral Supplementation of Probiotics in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","startDate":"2021-01-03","conditions":"Atopic Dermatitis","enrollment":98},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":"Diabetes Mellitus, Type I","enrollment":24},{"nctId":"NCT03018223","phase":"PHASE1","title":"Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-01-31","conditions":"Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia","enrollment":32},{"nctId":"NCT01790594","phase":"PHASE2","title":"Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-02","conditions":"Simultaneous Kidney and Pancreas Transplantation","enrollment":46},{"nctId":"NCT03602898","phase":"PHASE2","title":"Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-06-01","conditions":"Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia","enrollment":""},{"nctId":"NCT04900948","phase":"PHASE4","title":"Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of Life","status":"COMPLETED","sponsor":"National Medical Research Center for Children's Health, Russian Federation","startDate":"2017-12-10","conditions":"Atopic Dermatitis","enrollment":108},{"nctId":"NCT01760356","phase":"","title":"Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients","status":"TERMINATED","sponsor":"UDA Centro Nacional Hepato-Bilio-Pancreático","startDate":"2011-05-01","conditions":"End Stage Liver Disease, Rejection, Infection","enrollment":141},{"nctId":"NCT02544113","phase":"PHASE2","title":"A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2015-12","conditions":"Liver Failure","enrollment":110},{"nctId":"NCT04114097","phase":"PHASE4","title":"The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover","status":"COMPLETED","sponsor":"Jacob Thyssen","startDate":"2019-08-22","conditions":"Atopic Dermatitis, Atopic Eczema","enrollment":36},{"nctId":"NCT04765826","phase":"NA","title":"Comparison Between Systemic Steroids, Topical Steroids, or Calcineurin Inhibitors With Mini Punch Grafting in Treatment of Stable Non-segmental Vitiligo","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2021-01-25","conditions":"Vitiligo","enrollment":60},{"nctId":"NCT02474199","phase":"PHASE1, PHASE2","title":"Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-06-06","conditions":"Liver Transplant Recipient, Living Donor (of the Respective Liver Transplant Recipient)","enrollment":15},{"nctId":"NCT02334488","phase":"PHASE3","title":"Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2014-12-11","conditions":"Chronic Kidney Disease","enrollment":329},{"nctId":"NCT01936519","phase":"NA","title":"Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2013-12-16","conditions":"Immunosuppression, Renal Failure","enrollment":24},{"nctId":"NCT01921218","phase":"PHASE3","title":"Belatacept Therapy for the Failing Renal Allograft","status":"COMPLETED","sponsor":"Andrew B Adams","startDate":"2013-08","conditions":"Failing Renal Allograft","enrollment":13},{"nctId":"NCT04369183","phase":"","title":"Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2019-09-01","conditions":"Focal Segmental Glomerulosclerosis, Minimal Change Disease","enrollment":25},{"nctId":"NCT00377962","phase":"PHASE4","title":"Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-12","conditions":"Disorder Related to Cardiac Transplantation","enrollment":282},{"nctId":"NCT02394106","phase":"PHASE2","title":"Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome","status":"TERMINATED","sponsor":"Istituto Giannina Gaslini","startDate":"2015-07","conditions":"Nephrotic Syndrome","enrollment":13},{"nctId":"NCT04360031","phase":"","title":"The Effects of Microbiota Composition on Immunosuppression Protocols in Transplantation","status":"UNKNOWN","sponsor":"Université Catholique de Louvain","startDate":"2020-02-10","conditions":"Kidney Transplant; Complications, Immunosuppression, Transplant Failure","enrollment":100},{"nctId":"NCT01120028","phase":"PHASE2, PHASE3","title":"Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-09","conditions":"Kidney Transplantation","enrollment":852},{"nctId":"NCT04168944","phase":"PHASE2, PHASE3","title":"Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2019-11","conditions":"Hepatocellular Carcinoma","enrollment":108},{"nctId":"NCT03880643","phase":"","title":"Rituximab in Refractory Primary Membranous Nephropathy","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2018-11-01","conditions":"Glomerulonephritis, Membranous","enrollment":36},{"nctId":"NCT01379209","phase":"PHASE1, PHASE2","title":"Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)","status":"COMPLETED","sponsor":"Regimmune Corporation","startDate":"2011-09","conditions":"Graft Versus Host Disease","enrollment":68},{"nctId":"NCT01536535","phase":"PHASE4","title":"Predicting Response to Standardized Pediatric Colitis Therapy","status":"COMPLETED","sponsor":"Connecticut Children's Medical Center","startDate":"2012-07-10","conditions":"Ulcerative Colitis","enrollment":431},{"nctId":"NCT02949492","phase":"PHASE4","title":"Low-dose IL-2 for Treg Expansion and Tolerance (LITE)","status":"TERMINATED","sponsor":"King's College London","startDate":"2017-12-12","conditions":"Transplantation, Liver Diseases","enrollment":6},{"nctId":"NCT00866879","phase":"PHASE4","title":"Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-06","conditions":"Renal Transplant Rejection","enrollment":275},{"nctId":"NCT03886233","phase":"","title":"Treatment Outcome of Uveitis in Autoimmune Diseases","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-03","conditions":"Autoimmune Uveitis","enrollment":1},{"nctId":"NCT03834935","phase":"PHASE2, PHASE3","title":"Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba","status":"UNKNOWN","sponsor":"St Joseph University, Beirut, Lebanon","startDate":"2019-03-01","conditions":"Pityriasis Alba","enrollment":40},{"nctId":"NCT00135694","phase":"PHASE2","title":"Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-10","conditions":"Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure","enrollment":275},{"nctId":"NCT01950819","phase":"PHASE4","title":"Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-03","conditions":"End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis","enrollment":2037},{"nctId":"NCT02134899","phase":"PHASE3","title":"The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-10-14","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":3},{"nctId":"NCT01106833","phase":"PHASE2, PHASE3","title":"Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2010-04","conditions":"Chronic GVHD","enrollment":151},{"nctId":"NCT01473732","phase":"NA","title":"Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2012-03","conditions":"Chronic Allograft Injury, Calcineurin Inhibitor Toxicity","enrollment":2},{"nctId":"NCT00970073","phase":"NA","title":"Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2009-08","conditions":"Liver Transplantation","enrollment":30},{"nctId":"NCT01595984","phase":"PHASE3","title":"Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME)","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2012-05-03","conditions":"Kidney Failure","enrollment":90},{"nctId":"NCT03596970","phase":"PHASE3","title":"Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-09","conditions":"Liver Transplantation","enrollment":""},{"nctId":"NCT00214266","phase":"PHASE2","title":"A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2005-01","conditions":"Renal Transplantation","enrollment":31},{"nctId":"NCT01649609","phase":"NA","title":"Using mTOR Inhibitors in the Prevention of BK Nephropathy","status":"COMPLETED","sponsor":"Columbia University","startDate":"2012-03","conditions":"BK Viremia, BK Nephropathy","enrollment":40},{"nctId":"NCT01565616","phase":"PHASE2","title":"Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-03","conditions":"Sickle Cell Disease","enrollment":22},{"nctId":"NCT02730819","phase":"PHASE2","title":"Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-05-15","conditions":"Melasma","enrollment":19},{"nctId":"NCT00296296","phase":"PHASE4","title":"Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2005-06","conditions":"Kidney Transplant, Diabetes Mellitus, Type 2, Diabetic Nephropathy","enrollment":29},{"nctId":"NCT01436305","phase":"PHASE2","title":"Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":19},{"nctId":"NCT01517984","phase":"PHASE2","title":"Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-11","conditions":"Kidney Transplant Recipients","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":98,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["tacrolimus","cyclosporine"],"phase":"phase_3","status":"active","brandName":"Calcineurin inhibitor therapy","genericName":"Calcineurin inhibitor therapy","companyName":"Andrew B Adams","companyId":"andrew-b-adams","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Calcineurin inhibitors suppress T-cell activation by blocking the phosphatase calcineurin, preventing the dephosphorylation and nuclear translocation of NFAT transcription factors required for cytokine production. Used for Organ transplant rejection prophylaxis, Autoimmune and inflammatory disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}